Hypoxia imaging

Active Research Project
Investigator(s): 
Sadek Nehmeh, Ph.D.
Last Updated: 
June 14, 2022

By using 18 fluorodeoxyglucose (F)-labeled fluoromisonidazole (FMISO) PET imaging, Dr. Sadek Nehmeh assessed tumor hypoxia imaging in head-and-neck and lung cancer patients undergoing chemoradiation. In this work, compartmental kinetic modeling of FMISO-dynamic positron emission tomography (PET) images generated parametric maps of both tumor perfusion and tumor hypoxia. Identifying different tumor phenotypes based on the concordance/discordance between the two parametric maps, then implementing those findings in a dose-painting and dose-escalation radiotherapy scheme, is of particular interest. Currently, Dr. Nehmeh is leading a Phase I trial to simultaneously image tumor hypoxia and proliferation in glioblastoma by means of 18FMISO/18 fluorothymidine (FLT) PET.

Collaborators:

Dr. John Humm
Dr. Nancy Lee
Dr. Heiko Schode

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065